BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
Analysts largely viewed the miss as a significant blow to Ionis but not fatal for the company overall.…
Browsing Tag